Phase II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for Recurrent Malignant Astrocytic Gliomas

被引：0
|
作者：
Alexander M. Spence
Richard A. Peterson
Jeffrey D. Scharnhorst
Daniel L. Silbergeld
Robert C. Rostomily
机构：
[1] University of Washington,Department of Neurology, 356465
[2] University of Washington School of Medicine,Departments of Neurology and Neurological Surgery
来源：
Journal of Neuro-Oncology | 2004年 / 70卷
关键词：
anaplastic astrocytoma; glioblastoma multiforme; phase II; Tamoxifen; Temozolomide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose and background: The aim of this study was to assess the frequency of response and toxicity in adults with recurrent anaplastic astrocytoma (AA) or glioblastoma multiforme (GM) treated with concurrent continuous TMZ and TMX.
引用
收藏
页码：91 / 95
页数：4
相关论文
共 50 条
  • [31] PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
    Aoki, Tomokazu
    Arakawa, Yoshiki
    Ueba, Tetsuya
    Oda, Masashi
    Nishida, Namiko
    Akiyama, Yukinori
    Aoki, Tomokazu
    Iwasaki, Koichi
    Mikuni, Nobuhiro
    Miyamoto, Susumu
    NEURO-ONCOLOGY, 2020, 22 : 49 - 50
  • [32] Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
    Aoki, Tomokazu
    Arakawa, Yoshiki
    Ueba, Tetsuya
    Oda, Masashi
    Nishida, Namiko
    Akiyama, Yukinori
    Tsukahara, Tetsuya
    Iwasaki, Koichi
    Mikuni, Nobuhiro
    Miyamoto, Susumu
    NEUROLOGIA MEDICO-CHIRURGICA, 2017, 57 (01) : 17 - 27
  • [33] PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
    Aoki, T.
    Arakawa
    Ueba
    Oda
    Nishida
    Akiyama
    Tsukahara
    Iwasaki
    Mikuni
    Miyamoto
    NEURO-ONCOLOGY, 2017, 19 : 70 - 70
  • [34] PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
    Aoki, Tomokazu
    Arakawa, Yoshiki
    Ueba, Tetsuya
    Oda, Masashi
    Nishida, Namiko
    Akiyama, Yukinori
    Tsukahara, Tetsuya
    Iwasaki, Koichi
    Mikuni, Nobuhiro
    Miyamoto, Susumu
    NEURO-ONCOLOGY, 2016, 18 : 2 - 2
  • [35] PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
    Aoki, Tomokazu
    Arakawa, Yoshiki
    Ueba, Tetsuya
    Oda, Masashi
    Nishida, Namiko
    Akiyama, Yukinori
    Tukahara, Tetsuya
    Iwasaki, Koichi
    Mikuni, Nobuhiro
    Miyamoto, Susumu
    NEURO-ONCOLOGY, 2018, 20 : 25 - 25
  • [36] TREATMENT OF MALIGNANT SUPRATENTORIAL GLIOMAS WITH THE ASSOCIATION OF BCNU AND TAMOXIFEN - A PHASE-II STUDY
    LAFITTE, C
    LI, YJ
    AMERI, A
    CHAUVEINC, L
    POISSON, M
    DELATTRE, JY
    NEUROLOGY, 1994, 44 (04) : A308 - A308
  • [37] Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Omuro, Antonio
    Chan, Timothy A.
    Abrey, Lauren E.
    Khasraw, Mustafa
    Reiner, Anne S.
    Kaley, Thomas J.
    DeAngelis, Lisa M.
    Lassman, Andrew B.
    Nolan, Craig P.
    Gavrilovic, Igor T.
    Hormigo, Adilia
    Salvant, Cynthia
    Heguy, Adriana
    Kaufman, Andrew
    Huse, Jason T.
    Panageas, Katherine S.
    Hottinger, Andreas F.
    Mellinghoff, Ingo
    NEURO-ONCOLOGY, 2013, 15 (02) : 242 - 250
  • [38] PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Ney, Douglas
    Deangelis, Lisa
    Nolan, Craig
    Gavrilovic, Igor
    Hormigo, Adilia
    Lassman, Andrew
    Abrey, Lauren
    NEURO-ONCOLOGY, 2008, 10 (05) : 831 - 831
  • [39] Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas.
    Kesari, S.
    Schiff, D.
    Doherty, L.
    Gigas, D.
    Batchelor, T.
    Muzikansky, A.
    O'Neill, A.
    Drappatz, J.
    Kieran, M.
    Wen, P. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 75S - 75S
  • [40] Phase I/II study of vandetanib for patients with recurrent malignant gliomas.
    Mcnicol, K. A.
    Kreisl, T. N.
    Iwamoto, F. M.
    Sul, J.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345